Glibesyn

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glibesyn

Quick Facts

Property Description
Active ingredient Glibenclamide (Glyburide)
Form Oral Tablets (Standard and Micronized)
Pharmacological class Oral Hypoglycemic Agent, Second-Generation Sulfonylurea
General purpose Helps manage high blood sugar levels in Type 2 Diabetes
Origin Synthetic Compound

Glibesyn is a synthetic, prescription-only medication containing the active substance Glibenclamide, which is internationally recognized by its chemical synonym, Glyburide. It is an oral hypoglycemic agent and specifically belongs to the second-generation sulfonylurea class.

What Type of Medication is Glibesyn? (Identity and Class)

The core function of Glibesyn is derived from its origin as an N-sulfonylurea derivative, marking it as a compound manufactured through chemical synthesis. Its classification places it within the group of medicines used to manage high blood sugar levels (hyperglycemia) primarily associated with Type 2 diabetes mellitus. Glibenclamide is utilized for the management of non-insulin-dependent diabetes and serves for long-term glucose control in adult patient populations.

Composition, Form, and General Purpose (Form and Function)

Glibesyn is supplied as a single-active-ingredient product in the form of oral tablets, which is the intended route of administration. The medication is also available in specialized micronized tablets, where the reduced particle size of Glibenclamide is designed to affect its absorption profile in the body. The general purpose of the medication is to aid in glucose management by acting as an insulin secretagogue. This means Glibenclamide primarily stimulates the pancreatic beta cells to increase the release of pre-formed insulin into the bloodstream. Sulfonylureas, including Glibenclamide, exert their effects by targeting the ATP-sensitive potassium channels (KATP) on the pancreatic beta cell. This specific, clinically recognized mechanism is responsible for prompting the body to release the insulin necessary for lowering blood glucose.

Regulatory References

  1. NIH MedlinePlus Glyburide Information

What side effects are possible with Glibesyn?

Possible Side Effects and Safety Information

The safety profile of Glibesyn (Glibenclamide/Glyburide) is formally structured around adverse events categorized by frequency and the body system affected, based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

Classification Adverse Reaction System-Organ Class
Very Common Hypoglycemia (Low Blood Glucose) Metabolism and Nutrition Disorders
Common Diarrhea, Abdominal Pain/Discomfort Gastrointestinal Disorders
Rare Liver Function Abnormalities (Hepatitis, Jaundice) Hepatobiliary Disorders

Hypoglycemia is the most frequent adverse reaction, stemming from the medication's action as an insulin secretagogue. Less common effects include skin reactions (rashes, photosensitivity) and disturbances in the Blood and Lymphatic System such as hemolytic anemia.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation identifies severe and prolonged hypoglycemia as a potentially life-threatening event. Additionally, an elevated risk of cardiovascular mortality has been noted in epidemiological studies compared to certain other treatments.

Official labeling includes specific constraints regarding its use. The medication is generally restricted for use in cases of severe hepatic insufficiency and increases the risk of serious hypoglycemia in patients with renal impairment. The safety and effectiveness of Glibesyn have not been established in the pediatric population.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Glibesyn (Glipizide)


Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations: Hypoglycemia (low blood sugar)
Physiological systems affected (as stated in label): Metabolic (glucose levels), potentially affecting the Central Nervous System
Dose-related or exposure-related factors (if applicable): Overdosage of sulfonylureas is capable of producing severe hypoglycemia.

| Population-specific overdose notes (if applicable): | Elderly, debilitated, or malnourished patients, and those with adrenal, pituitary, hepatic, or renal insufficiency are especially susceptible to this effect. | | Emergency-response statements (as written in official documents): | If a patient is comatose or not fully alert, rapid intravenous (I.V.) glucose infusion must be administered. | When immediate medical help is required (label-derived phrasing only): | Severe hypoglycemic reactions with coma, seizure, or other neurological impairment constitute medical emergencies requiring immediate hospitalization.


Overdose classifications (high-level)

Feature Official Regulatory Statement
Severity classification (as defined in official documents): Severe hypoglycemia (capable of causing permanent brain impairment or death)
Regulatory basis (EMA / FDA / etc.): FDA (United States)
Overdose-context constraints (as defined in official documents): Hypoglycemia may recur after apparent clinical recovery.

Resulting overdose structure

Official overdose statements:

  • Overdose of this drug class is capable of causing severe hypoglycemia.
  • Severe hypoglycemia can lead to unconsciousness, convulsions, or other neurological impairment.
  • If a patient is comatose or not fully alert, they require immediate hospitalization and rapid intravenous glucose.
  • Patients must be closely monitored for a minimum of 24 to 48 hours following overdose or severe reaction, as blood sugar levels may drop again.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose risk for Glibesyn primarily as severe, profound, and potentially prolonged hypoglycemia. This condition requires urgent medical attention due to the high risk of serious outcomes, including permanent neurological damage or death. The mandated emergency response centers on immediately correcting low blood sugar with intravenous glucose and ensuring extended, close monitoring for 24 to 48 hours to prevent recurrence.

Therapeutic Uses of Glibesyn

What Glibesyn Treats: Main Uses and Benefits

Glibesyn (Glibenclamide/Glyburide) is commonly used to help with managing the symptoms of Type 2 diabetes mellitus in adults. This medication is considered relevant for the chronic condition when sustained elevation of blood glucose exists, and proper dietary and exercise regimens alone are insufficient. It provides supportive relief that supports general well-being during symptomatic phases.

The use of Glibesyn is relevant to the management of chronic high blood sugar, symptoms related to physical discomfort, and the need for long-term metabolic support. The therapy assists in addressing the disruptive manifestations of glucose overload, such as excessive thirst and frequent or increased urination. Stabilizing blood sugar levels may help ease the overall symptom load linked to chronic hyperglycemia, and assists with maintaining functional stability in organ systems like the eyes, nerves, and kidneys over time.

Quick Fact: Symptom Relief Description
Primary Domain Management of symptoms related to sustained high blood glucose
Key Benefit Helps ease the symptom burden during periods of discomfort
Usage Context Support for conditions involving episodic or fluctuating manifestations, as an adjunct to diet/exercise

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Glibesyn is indicated for use in adults with Type 2 diabetes mellitus whose blood sugar levels are not adequately controlled by diet and exercise alone. Eligibility is strictly defined by the absence of specific conditions that are listed as contraindications in official regulatory documents.

Population Group Eligibility Status
Type 1 Diabetes Contraindicated
Diabetic Ketoacidosis/Pre-Coma Contraindicated
Severe Hepatic (Liver) Impairment Contraindicated
Severe Renal (Kidney) Impairment Contraindicated
Pregnancy and Lactation Contraindicated (Must switch to insulin)
Allergy to Sulfonylureas or Sulfonamides Contraindicated

Use is not recommended in children as safety and effectiveness have generally not been established for this age group, and the medicine is typically not used for children's forms of diabetes. Older adults require special caution and a conservative starting dose due to a heightened risk of developing low blood sugar (hypoglycemia). Use may also be restricted or require a temporary change to insulin during periods of unusual stress, such as severe infection, trauma, or major surgery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions of Glibesyn (Glibenclamide/Glyburide) with other medicines and substances, as documented in official regulatory labeling.

Contraindicated Combinations

Co-administration is strictly prohibited with Bosentan due to the risk of hepatotoxicity linked to the inhibition of the Bile Salt Export Pump (BSEP). Additionally, oral Miconazole is contraindicated due to the high risk of severe hypoglycemia.

Pharmacokinetic and Pharmacodynamic Interference

Glibesyn is primarily metabolized by the CYP2C9 and, to a lesser extent, the CYP3A4 enzyme systems. Strong inhibitors (e.g., Fluconazole, Clarithromycin) or inducers (e.g., Rifampin) of these enzymes can significantly alter Glibesyn exposure, necessitating cautious co-administration.

Interacting medicines are often classified by their effect on blood glucose:

  • Potentiating the effect (risk of hypoglycemia): Includes medicines such as ACE inhibitors (e.g., Captopril), NSAIDs, and Salicylates.
  • Weakening the effect (risk of hyperglycemia): Includes medicines such as Thiazide diuretics and Corticosteroids.

Additional Interaction Notes

Sympatholytic drugs (e.g., Beta-blockers) may mask the typical warning signs of hypoglycemia. Furthermore, severe renal or hepatic impairment can diminish Glibesyn clearance, leading to accumulation and increased risk of prolonged hypoglycemia. The label advises a time separation, such as taking an oral suspension 15 minutes before feeding, for specific populations.

Mechanism of Action

How Glibesyn Works

The action of Glibesyn (Glibenclamide) is defined by a highly specific, three-stage biological cascade that compels the release of insulin. The mechanism operates entirely by modulating ion channels on the insulin-producing beta-cells of the pancreas.


Modulating the Pancreatic K ATP Channel

Glibesyn initiates its effect by acting as an inhibitor on the ATP-sensitive potassium channel ( K ATP channel), specifically targeting the Sulfonylurea Receptor 1 (SUR1) subunit on pancreatic beta-cells. This targeted molecular blockade prevents potassium ions ( K^+) from exiting the cell, which is the necessary first step to electrically activate the cell and trigger its core function.


Calcium-Dependent Secretagogue Cascade

The prevention of potassium efflux causes the beta-cell membrane to depolarize (undergo electrical activation), forcing the immediate opening of voltage-gated Ca^2+ channels. The resulting massive influx of Ca^2+ serves as the intracellular signal that triggers the process of exocytosis, leading to the forced, non-physiological release of insulin into the portal circulation.


Systemic Influence on Glucose Distribution

The direct consequence of the drug's mechanism is an increase in systemic insulin concentration. This elevated level of insulin influences the body's systemic distribution of glucose by promoting the translocation of glucose into muscle and fat tissue and reducing hepatic glucose output. The mechanism requires the presence of functional pancreatic beta-cells to synthesize and store the hormone.

Dosage and Administration Information

Administration Guidelines for Glibesyn (Glibenclamide/Glyburide)

Feature Instruction Summary
Route of Administration Glibesyn is administered orally in tablet form (standard or micronized).
Timing with Meals The medication is taken with breakfast or the first main meal of the day.
Missed Dose Rule If a dose is missed, the forgotten dose is skipped and the regular schedule is resumed; doses are not doubled.

The use of Glibesyn follows specific dosing parameters. The standard tablet is typically initiated at 2.5 mg to 5 mg once daily, with a maximum recommended daily dose of 20 mg. The micronized tablet is typically initiated at 1.5 mg to 3 mg once daily, with a lower maximum dose of 12 mg/day. Dose adjustments are generally performed in small increments at weekly intervals based on clinical response.

Frequency and Special Conditions

Most regimens begin with a once-daily frequency. However, if the total daily dose exceeds a certain threshold (e.g., 10 mg for the standard tablet), the dose may be administered in divided doses (twice daily). Special caution is applied when dosing older adults (geriatric patients), who are typically started on the lowest available dose (e.g., 1.25 mg standard or 0.75 mg micronized) and titrated conservatively. The medication is intended as part of a long-term treatment plan and is used when a regular meal schedule, particularly consistent breakfast intake, can be maintained.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Glibesyn

Glibesyn was evaluated in research settings for patients with Type 2 Diabetes Mellitus, conditions where symptoms may vary in intensity. Research examined biomarkers related to systemic or functional imbalance. The core evidence comes from a variety of sources, including randomized controlled trials (RCTs), systematic reviews, and studies observing responses over defined time intervals.

Research examined how studies monitored glucose control markers in comparison to placebo, other sulfonylureas, or other oral diabetes medications. Findings describe patterns observed in the studies related to glucose levels over the study period. Data show patterns related to how the medicine was observed: research describes a non-proportional relationship, meaning that increasing the dosage beyond a certain point was associated with measurements that did not change proportionally in blood sugar or insulin levels.

Evidence for Use in Gestational Diabetes Mellitus (GDM)

Glibesyn was studied for its use in pregnant women diagnosed with Gestational Diabetes Mellitus (GDM). Research primarily relies on randomized controlled trials and subsequent systematic reviews that compare Glibesyn was evaluated against insulin, the traditional comparator in this setting. These studies monitored parameters related to maternal glucose control and also examined various neonatal measures.

Findings indicate that studies monitored maternal blood sugar levels in both the Glibesyn and insulin groups. However, when examining measures in the infants, the evidence suggests that certain findings were mixed. Data show patterns related to an increased measurement of neonatal hypoglycemia when Glibesyn was observed in some studies. Furthermore, results related to the incidence of macrosomia showed inconsistencies, with some subgroup analyses reporting that patterns of macrosomia were observed in the Glibesyn group.

Research Gaps and Uncertainties

While research has explored the long-term observation of measured outcomes, long-term effects are not fully established. Evidence quality varies across studies, with some comparative trials having suboptimal reporting. Additionally, comparative evidence is lacking or inconsistent regarding certain neonatal parameters. There is also limited information for long-term outcomes in the children of mothers who received Glibesyn.

Key Studies & References

  1. Glibenclamide (Glyburide): Clinical Pharmacology and Mechanisms of Hypoglycemic Action
  2. Glibenclamide (Glyburide) in the management of Type 2 Diabetes Mellitus: NIH MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Glibesyn (FAQ)


Q: How quickly should I expect Glibesyn to start working?

Official product information, based on pharmacokinetic data, indicates that the active ingredient in Glibesyn (glibenclamide) is significantly absorbed into the body within about one hour after a single dose. Peak concentration, or the highest level of the drug in the bloodstream, is usually reached in approximately four hours.


Q: Is weight gain a common side effect of taking Glibesyn?

Weight gain is listed as an undesirable effect in some official product information for glibenclamide. Concerns about changes in body weight are best addressed with a healthcare provider.


Q: What are the signs or symptoms of hypoglycemia I should watch out for when taking Glibesyn?

Official safety information notes that hypoglycemia (low blood sugar) is the most frequent side effect. Common symptoms of low blood sugar that are listed include feeling shaky or anxious, sweating, looking pale, feeling dizzy, and experiencing a fast heart rate or confusion.


Q: Is it normal to have stomach upset like nausea or heartburn after starting Glibesyn?

Yes, regulatory documents list nausea and heartburn as commonly reported side effects of Glibesyn. Gastrointestinal issues such as diarrhea and abdominal discomfort are also frequently reported.


Q: Are there any specific lifestyle changes, like diet or exercise, that must be followed while taking Glibesyn?

The labeling emphasizes that for the best clinical outcome, Glibesyn is intended to be used alongside adherence to dietary instructions, including a regular meal schedule (especially breakfast), and a regular exercise program. This combination is noted as important for managing high blood sugar levels.


Q: Can common medications like NSAIDs or certain blood pressure drugs interact with Glibesyn?

Yes, regulatory drug interaction information confirms that Glibesyn's blood sugar-lowering effect may be increased (potentiated) by certain other drugs. This includes certain nonsteroidal anti-inflammatory agents (NSAIDs) and some beta-adrenergic blocking agents (a class of blood pressure medicine).


Q: What other diabetes medicines interact with Glibesyn?

Using Glibesyn in combination with other drugs intended to lower blood sugar, including insulin, increases the risk of hypoglycemia. While combination therapy with metformin may have a synergistic effect, a heightened risk of low blood sugar is associated with this combined use.


Q: Why is Glibesyn contraindicated for people with Diabetic Ketoacidosis (DKA)?

Official product information explains that Glibesyn's mechanism of action requires the presence of functioning beta cells in the pancreas to stimulate insulin release. Diabetic Ketoacidosis (DKA) is a severe condition marked by an acute and major lack of insulin, meaning the drug's core mechanism will not be effective.


Q: Does Glibesyn affect my risk for cardiovascular problems or heart disease?

Official safety information includes a constraint noting an elevated risk. Some epidemiological studies have shown an increased risk of cardiovascular mortality compared to treatment with diet alone or diet plus insulin. Concerns regarding this risk are best addressed with a healthcare provider.


Q: Is it true that Glibesyn works by stimulating the pancreas?

Yes, according to official product information, Glibesyn is an orally active hypoglycemic agent. Its primary function is to stimulate the release of insulin that has been stored in the pancreas.


Q: Why is Glibesyn sometimes used to treat Gestational Diabetes (off-label use)?

Glibesyn is typically contraindicated (not recommended) for use during pregnancy, though it has been evaluated in clinical studies for Gestational Diabetes Mellitus (GDM), where it was compared against insulin. Research findings on GDM use were mixed, and some studies reported an increased risk of neonatal hypoglycemia.


Q: How should Glibesyn be stored?

Official guidelines state that Glibesyn should be stored at controlled room temperature, which is generally between 20 C to 25 C (68 F to 77 F). The medication should be kept in a tight, light-resistant container and away from excessive heat, light, and moisture.


Q: Can Glibesyn lose its effectiveness over time (secondary failure)?

Yes, regulatory labeling addresses the possibility of 'secondary failure,' where the drug's effectiveness may diminish over time. This can be due to the natural progression of Type 2 diabetes or a reduced responsiveness to the drug.


Q: What happens if Glibesyn is taken without a meal?

Official instructions advise taking Glibesyn with breakfast or the first main meal. The risk of hypoglycemia (low blood sugar) is increased when the medication is taken without sufficient food, as this would result in deficient caloric intake.


Q: Why do some people take Glibesyn twice a day instead of once?

Official dosage information states that when the total daily dose is above a certain amount, it may be divided into two separate doses to help achieve better and more consistent glucose control.


Q: Why do some people report feeling shaky or anxious after taking Glibesyn?

These sensations—feeling shaky or anxious—are recognized symptoms of hypoglycemia (low blood sugar). Hypoglycemia is the most frequent adverse reaction associated with Glibesyn due to its mechanism of increasing insulin release.


Q: Does Glibesyn interact with oral contraceptives?

Yes. Regulatory documents note that certain medications, including oral contraceptives, tend to promote hyperglycemia (high blood sugar). Taking Glibesyn with these drugs may lead to a loss of the expected blood glucose control.


Q: What is the purpose of Glibesyn in combination with Metformin?

The combination of glibenclamide and metformin is typically used when diet, exercise, and the maximum dose of Glibesyn alone are no longer enough to control blood sugar. The two agents work through different, complementary mechanisms to improve overall glucose tolerance.


Q: Why is it important to follow diet and exercise advice when taking Glibesyn?

The management of high blood sugar levels typically involves following dietary instructions and engaging in a regular exercise program. Official information states that not following a regular meal schedule, for instance, increases the risk of hypoglycemia when taking Glibesyn.


Q: Does taking Glibesyn affect a person's ability to drive?

Official information indicates that Glibesyn is not known to directly affect the ability to drive or operate machinery. However, this is only true unless a person is experiencing low blood sugar (hypoglycemia), as this condition can impair concentration and alertness.

How should Glibesyn be stored and disposed of?

How to Store and Dispose of Glibenclamide (Glibesyn)

The storage and disposal of Glibenclamide are defined by regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Detail Requirement
Temperature Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep in a tight, light-resistant container and in the original packaging to avoid excessive heat, light, and moisture.
Safety Store out of the reach and sight of children.
Stability Do not use the tablets after the expiry date shown on the label.

Disposal Instructions

Unused or expired Glibenclamide must not be disposed of via wastewater or household trash. Individuals must consult a pharmacist for proper disposal instructions according to local regulations to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glibesyn found in:

A-Z Index: